Medical Device Deals Update, October 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced August-October 2013.
You may also be interested in...
Germany's Ministry of Health surprised all those present at a recent BAH meeting by announcing it would like to see erectile dysfunction drugs like sildenafil and tadalafil available OTC. Such a move, however, would put the government at odds with drug regulator BfArM's Expert Committee for Prescription, which recently rejected an application for the Rx-to-OTC switch of sildenafil.
Two oncology chiefs from the French firm talked to Scrip about how its pipeline echoes the emerging intersection between precision medicine and immuno-oncology and how biology is taking precedence over technology in cancer R&D.
Ascarit is seeking UK approval for the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for its white mulberry-based dietary supplement. It will be just the second claim assessed by the UK Nutrition and Health Claims Committee which took over the role from EFSA on 1 January 2021 following Brexit.